Naber, Steffie KBruijning-Verhagen, Patricia C J Lde Hoog, Marieke L Avan Giessen, Anoukh2020-08-162020-08-162020-04-091873-25183211529710.1016/j.vaccine.2020.01.057http://hdl.handle.net/10029/624144enCost-effectivenessHigh-risk medical conditionInfluenza vaccinationCost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands.ArticleVaccine 2020; 38(17):3387-96